<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02054351</url>
  </required_header>
  <id_info>
    <org_study_id>GM-IMAB-002-01</org_study_id>
    <secondary_id>2013-002755-15</secondary_id>
    <nct_id>NCT02054351</nct_id>
  </id_info>
  <brief_title>Phase 1 Trial of IMAB027 in Patients With Recurrent Advanced Ovarian Cancer (OVAR)</brief_title>
  <acronym>OVAR</acronym>
  <official_title>A First-in-human Dose Escalation and Dose Finding Phase 1 Trial of IMAB027 in Patients With Recurrent Advanced Ovarian Cancer (OVAR)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Ganymed Pharmaceuticals GmbH</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Astellas Pharma Inc</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Advanced ovarian cancer is a high medical need indication. Cure is not available to these
      patients and treatment has palliative intent. A proportion of advanced stage ovarian cancer
      expresses substantial levels of Claudin 6 (CLDN6), a carcino-embryonic transmembrane protein,
      which is absent from normal adult human tissue. IMAB027 is a monoclonal antibody that binds
      to CLDN6. Preclinically IMAB027 was shown to inhibit tumor growth and to kill cancer cells by
      antibody-dependent cellular cytotoxicity and complement-dependent cytotoxicity. This trial is
      a first-in-human dose escalation and dose finding Phase 1 trial of IMAB027 in patients with
      recurrent advanced ovarian cancer to assess the safety and tolerability, the
      pharmacokinetics, the antitumoral activity and the immunogenicity of IMAB027.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>December 2013</start_date>
  <completion_date type="Actual">March 21, 2017</completion_date>
  <primary_completion_date type="Actual">March 2017</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Safety and tolerability</measure>
    <time_frame>24 month</time_frame>
    <description>Safety profile including type, frequency, severity, relationship of adverse events to investigational medicinal product, dose limiting toxicities, maximum tolerated dose</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>to assess pharmacokinetics</measure>
    <time_frame>24 month</time_frame>
    <description>Cmax, AUC, terminal half-life and related pharmacokinetic parameters of IMAB027</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>to assess antitumoral activity</measure>
    <time_frame>up to 3 years</time_frame>
    <description>Disease control rates (CR, PR, SD), ratio previous/current remission time intervals and overall survival</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>to assess immunogenicity</measure>
    <time_frame>24 month</time_frame>
    <description>Frequency of anti-IMAB027 antibodies</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">72</enrollment>
  <condition>Ovarian Cancer</condition>
  <arm_group>
    <arm_group_label>IMAB027 administration</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Monotherapy - different dose Levels.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>IMAB027</intervention_name>
    <description>Stage 1 (Intrapatient dose escalation): The starting dose is set to 1 mg/m2, followed by 10 mg/m2, 30 mg/m2 and 100 mg/m2 Stage 2 (Interpatient dose escalation): 4 dose level 100 mg/m2, 300 mg/m2, 600 mg/m2, 1000 mg/m2 Extension period: 4 dose level 100 mg/m2, 300 mg/m2, 600 mg/m2, 1000 mg/m2</description>
    <arm_group_label>IMAB027 administration</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Signed written informed consent

          2. Female patients ≥18 years of age, no upper age limit

          3. Histologically or cytologically confirmed CLDN6+ ovarian cancer of any histology type
             including primary peritoneal or fallopian tube tumors (histological documentation of
             the original primary tumor is required via a pathology report)

          4. Performance status ECOG 0-2

          5. Patients with measurable, non-measurable, or evaluable disease: Evaluable disease:
             defined as a confirmed CA-125 ≥2 x ULN, Measurable disease (RECIST 1.1): defined as at
             least one lesion that can be accurately measured in at least one dimension

          6. Availability of a FFPE tumor tissue sample or tumor cell positive paracentesis fluid
             samples (abdominal or pleural cavity) for the assessment of CLDN6 positivity

          7. Life expectancy of &gt;12 weeks

          8. Adequate organ function defined as:

             Adequate hematologic function (ANC ≥1000/μl, platelets ≥100.000/μl, hemoglobin ≥9.0
             g/dl (can be post transfusion)); Adequate renal function (serum creatinine ≤1.5 mg/dl
             [114.5 μmol/l] or creatinine clearance rate ≥30 ml/min); Adequate liver function
             (serum total bilirubin ≤2 x ULN, AST/ALT ≤3 x ULN)

          9. Patients of child-bearing potential must have a negative β-HCG urine test within 72
             hours before receiving treatment

        Exclusion Criteria:

          1. Patient is pregnant or breast-feeding

          2. Prior allergic reaction or intolerance to a monoclonal antibody (humanized or
             chimeric)

          3. Any prior anti-tumor therapy within 14 days prior to the start of IMAB027 treatment

          4. Other concurrent anticancer therapies

          5. HIV infection in medical history or active Hepatitis B or C infection requiring
             treatment

          6. History of any one or more of the following cardiovascular conditions within the past
             6 months: Myocardial infarction (T-Wave/Non-T-Wave), Unstable angina pectoris Class
             II, III or IV congestive heart failure as defined by the New York Heart Association
             (NYHA), History of cerebrovascular accident, pulmonary embolism or untreated deep
             venous thrombosis (DVT). Patients with recent DVT who have been or are treated with
             therapeutic anti-coagulant agents (excluding warfarin) for at least 6 weeks are
             eligible

          7. Other investigational agents or devices concurrently or within 14 days before start of
             IMAB027 treatment

          8. Any hemoptysis or bleeding event that is clinically relevant within 2 weeks of first
             dose of study drug

          9. Clinical symptoms of brain metastases or tumor-associated spinal cord compression

         10. Need for continuous, systemic immunosuppressive therapy

         11. Any other medical condition that would, in the opinion of the Investigator, limit the
             patient's ability to complete the study
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Dirk Jaeger, Prof. Dr.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Nationales Zentrum für Tumorerkrankungen, Heidelberg</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>UZ Brussels</name>
      <address>
        <city>Brussels</city>
        <zip>1090</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>UZ Leuven</name>
      <address>
        <city>Leuven</city>
        <zip>3000</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Nationales Centrum für Tumorerkrankungen (NCT) Heidelberg, Universitätsklinikum Heidelberg</name>
      <address>
        <city>Heidelberg</city>
        <state>Baden-Württemberg</state>
        <zip>69120</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitäts-Frauenklinik (UFK) Tübingen</name>
      <address>
        <city>Tübingen</city>
        <state>Baden-Württemberg</state>
        <zip>72076</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitätsklinikum Ulm, Frauenklinik</name>
      <address>
        <city>Ulm</city>
        <state>Baden-Württemberg</state>
        <zip>89075</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitätsmedizin Mainz</name>
      <address>
        <city>Mainz</city>
        <state>Rheinland-Pfalz</state>
        <zip>55131</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Gemeinschaftspraxis Hämatologie-Onkologie</name>
      <address>
        <city>Dresden</city>
        <state>Sachsen</state>
        <zip>1307</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>UKSH Kiel</name>
      <address>
        <city>Kiel</city>
        <state>Schleswig-Holstein</state>
        <zip>24105</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Charité - Universitätsmedizin Berlin</name>
      <address>
        <city>Berlin</city>
        <zip>13353</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Belgium</country>
    <country>Germany</country>
  </location_countries>
  <verification_date>June 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 29, 2014</study_first_submitted>
  <study_first_submitted_qc>February 3, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 4, 2014</study_first_posted>
  <last_update_submitted>June 30, 2017</last_update_submitted>
  <last_update_submitted_qc>June 30, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">July 2, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Advanced ovarian cancer</keyword>
  <keyword>CLDN6 positive</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ovarian Neoplasms</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

